Pharmacological Management of Apathy in Dementia.
Journal
CNS drugs
ISSN: 1179-1934
Titre abrégé: CNS Drugs
Pays: New Zealand
ID NLM: 9431220
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
accepted:
21
11
2021
pubmed:
11
1
2022
medline:
23
3
2022
entrez:
10
1
2022
Statut:
ppublish
Résumé
Apathy is a highly prevalent symptom of dementia. Despite its association with faster cognitive and functional decline, decreased quality of life and increased mortality, no therapies are currently approved to treat apathy. The objective of this review was to summarize the drugs that have been studied for apathy treatment in patients with dementia (specifically Alzheimer's disease [AD], Huntington's disease [HD] and Parkinson's disease [PD] dementia; dementia with Lewy bodies [DLB]; vascular dementia [VaD]; and frontotemporal dementia [FTD]) based on their putative mechanisms of action. A search for relevant studies was performed using ClinicalTrials.gov and PubMed. Eligible studies were randomized controlled trials that were available in English and included at least one drug intervention and an apathy measure scale. A total of 52 studies that included patients with AD (n = 33 studies), PD (n = 5), HD (n = 1), DLB (n = 1), FTD (n = 3), VaD (n = 1), VaD and AD (n = 4), VaD and mixed dementia (n = 1), and AD, VaD and mixed dementia (n = 3) were eligible for inclusion. These studies showed that methylphenidate, olanzapine, cholinesterase inhibitors, choline alphoscerate, citalopram, memantine, and mibampator are the only beneficial drugs in AD-related apathy. For PD-related apathy, only methylphenidate, rotigotine and rivastigmine showed benefits. Regarding FTD- and DLB-related apathy, initial studies with agomelatine and rivastigmine showed benefits, respectively. As for HD- and only-VaD-related apathy, no drugs demonstrated benefits. With regards to mixed populations, memantine, galantamine and gingko biloba showed effects on apathy in the AD plus VaD populations and nimodipine in the VaD plus mixed dementia populations. Of the drugs with positive results, some are already prescribed to patients with dementia to target other symptoms, some have characteristics-such as medical contraindications (e.g., cardiovascular) and adverse effects (e.g., gastrointestinal disturbances)-that limit their clinical use and some require further study. Future studies should investigate apathy as a primary outcome, making use of appropriate sample sizes and study durations to ensure durability of results. There should also be a consensus on using scales with high test/retest and interrater reliabilities to limit the inconsistencies between clinical trials. In conclusion, there are currently no US FDA-approved drugs that target apathy in dementia, so there is an ongoing need for the development of such drugs.
Identifiants
pubmed: 35006557
doi: 10.1007/s40263-021-00883-0
pii: 10.1007/s40263-021-00883-0
doi:
Substances chimiques
Central Nervous System Stimulants
0
Dopamine Agonists
0
Serotonin Uptake Inhibitors
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
143-165Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Chang F, Patel T, Schulz ME. The “Rising Tide” of dementia in Canada: what does it mean for pharmacists and the people they care for? Can Pharm J (Ott). 2015;148(4):193–9.
pmcid: 4530360
Prince M, Wimo A, Guerchet M, Ali G-C, Wu Y-T, Prina M. World Alzheimer Report 2015. The global impact of dementia. An analysis of prevalence, incidence, cost and trends. 2015.
Duong S, Patel T, Chang F. Dementia: what pharmacists need to know. Can Pharm J (Ott). 2017;150(2):118–29.
pmcid: 5384525
Cerejeira J, Lagarto L, Mukaetova-Ladinska EB. Behavioral and psychological symptoms of dementia. Front Neurol. 2012;3:73.
pubmed: 22586419
pmcid: 3345875
Marin RS. Apathy: a neuropsychiatric syndrome. J Neuropsychiatry Clin Neurosci. 1991;3(3):243–54.
pubmed: 1821241
Starkstein SE, Jorge R, Mizrahi R, Robinson RG. A prospective longitudinal study of apathy in Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 2006;77(1):8.
pubmed: 16361584
pmcid: 2117400
Devanand DP, Brockington CD, Moody BJ, Brown RP, Mayeux R, Endicott J, et al. Behavioral syndromes in Alzheimer’s disease. Int Psychogeriatr. 1992;4(4):161–84.
pubmed: 1288661
Gonzales-Salvador T, Lyketsos C, Baker A, Roques C, Hovanek L, Steele C, et al. Quality of life of patients with dementia in long-term care. Int J Geriatr Psychiatry. 2000;15(2):181–9.
Nijsten JMH, Leontjevas R, Pat-El R, Smalbrugge M, Koopmans R, Gerritsen DL. Apathy: risk factor for mortality in nursing home patients. J Am Geriatr Soc. 2017;65(10):2182–9.
pubmed: 28791690
Akyol MA, Küçükgüçlü Ö, Yener G. Investigation of factors affecting apathy in three major types of dementia. Noro Psikiyatr Ars. 2019;57(2):120–5.
pubmed: 32550777
pmcid: 7285638
Breitve MH, Brønnick K, Chwiszczuk LJ, Hynninen MJ, Aarsland D, Rongve A. Apathy is associated with faster global cognitive decline and early nursing home admission in dementia with Lewy bodies. Alzheimers Res Ther. 2018;10(1):83.
pubmed: 30121084
pmcid: 6098842
Bonfanti AB, Etcheverry JL, Persi GG, Zezza H, Starkstein S, Gatto EM. Apathy in Parkinson’s disease. Impairment in quality of life. Medicina (B Aires). 2009;69(2):253–8.
Camacho MBR, Mason SL. Apathy in Huntington’s disease: a review of the current conceptualization. J Alzheimers Dis Parkinsonism. 2018;8:431.
Robert P, Lanctôt KL, Agüera-Ortiz L, Aalten P, Bremond F, Defrancesco M, et al. Is it time to revise the diagnostic criteria for apathy in brain disorders? The 2018 international consensus group. Eur Psychiatry. 2018;54:71–6.
pubmed: 30125783
Miller DS, Robert P, Ereshefsky L, Adler L, Bateman D, Cummings J, et al. Diagnostic criteria for apathy in neurocognitive disorders. Alzheimers Dement. 2021. https://doi.org/10.1002/alz.12358 .
Le Heron C, Apps MAJ, Husain M. The anatomy of apathy: a neurocognitive framework for amotivated behaviour. Neuropsychologia. 2018;118:54–67.
pubmed: 28689673
pmcid: 6200857
Le Heron C, Holroyd CB, Salamone J, Husain M. Brain mechanisms underlying apathy. J Neurol Neurosurg Psychiatry. 2019;90(3):302–12.
pubmed: 30366958
Mitchell RA, Herrmann N, Lanctôt KL. The role of dopamine in symptoms and treatment of apathy in Alzheimer’s disease. CNS Neurosci Ther. 2011;17(5):411–27.
pubmed: 20560994
Brodaty H, Burns K. Nonpharmacological management of apathy in dementia: a systematic review. Am J Geriatr Psychiatry. 2012;20(7):549–64.
pubmed: 21860324
Sterne JACSJ, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng H-Y, Corbett MS, Eldridge SM, Hernán MA, Hopewell S, Hróbjartsson A, Junqueira DR, Jüni P, Kirkham JJ, Lasserson T, Li T, McAleenan A, Reeves BC, Shepperd S, Shrier I, Stewart LA, Tilling K, White IR, Whiting PF, Higgins JPT. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.
pubmed: 31462531
Juárez Olguín H, Calderón Guzmán D, Hernández García E, Barragán MG. The role of dopamine and its dysfunction as a consequence of oxidative stress. Oxid Med Cell Longev. 2016;2016:9730467.
pubmed: 26770661
Pan X, Kaminga AC, Wen SW, Wu X, Acheampong K, Liu A. Dopamine and dopamine receptors in Alzheimer’s disease: a systematic review and network meta-analysis. Front Aging Neurosci. 2019;11:175.
pubmed: 31354471
pmcid: 6637734
Gratwicke J, Jahanshahi M, Foltynie T. Parkinson’s disease dementia: a neural networks perspective. Brain. 2015;138(6):1454–76.
pubmed: 25888551
pmcid: 4614131
Narayanan NS, Rodnitzky RL, Uc EY. Prefrontal dopamine signaling and cognitive symptoms of Parkinson’s disease. Rev Neurosci. 2013;24(3):267–78.
pubmed: 23729617
Bäckman L, Farde L. Dopamine and cognitive functioning: Brain imaging findings in Huntington’s disease and normal aging. Scand J Psychol. 2001;42(3):287–96.
pubmed: 11501742
Murley AG, Rowe JB. Neurotransmitter deficits from frontotemporal lobar degeneration. Brain. 2018;141(5):1263–85.
pubmed: 29373632
pmcid: 5917782
Piggott MA, Marshall EF, Thomas N, Lloyd S, Court JA, Jaros E, et al. Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer’s and Parkinson’s diseases: rostrocaudal distribution. Brain. 1999;122(Pt 8):1449–68.
pubmed: 10430831
Court JA, Perry EK. Neurotransmitter abnormalities in vascular dementia. Int Psychogeriatr. 2003;15(Suppl 1):81–7.
pubmed: 16191222
Herrmann N, Rothenburg LS, Black SE, Ryan M, Liu BA, Busto UE, et al. Methylphenidate for the treatment of apathy in Alzheimer disease: prediction of response using dextroamphetamine challenge. J Clin Psychopharmacol. 2008;28(3):296–301.
pubmed: 18480686
Padala PR, Padala KP, Lensing SY, Ramirez D, Monga V, Bopp MM, et al. Methylphenidate for apathy in community-dwelling older veterans with mild Alzheimer’s disease: a double-blind, randomized placebo-controlled trial. Am J Psychiatry. 2018;175(2):159–68.
pubmed: 28945120
Rosenberg PB, Lanctôt KL, Drye LT, Herrmann N, Scherer RW, Bachman DL, et al. Safety and efficacy of methylphenidate for apathy in Alzheimer’s disease: a randomized, placebo-controlled trial. J Clin Psychiatry. 2013;74(8):810–6.
pubmed: 24021498
pmcid: 3902018
Mintzer J, Lanctôt KL, Scherer RW, Rosenberg PB, Herrmann N, van Dyck CH, et al. Effect of methylphenidate on apathy in patients with Alzheimer disease: the ADMET 2 randomized clinical trial. JAMA Neurol. 2021;78(11):1324–1332.
pubmed: 34570180
Frakey LL, Salloway S, Buelow M, Malloy P. A randomized, double-blind, placebo-controlled trial of modafinil for the treatment of apathy in individuals with mild-to-moderate Alzheimer’s disease. J Clin Psychiatry. 2012;73(6):796–801.
pubmed: 22687392
Nave S, Doody RS, Boada M, Grimmer T, Savola J-M, Delmar P, et al. Sembragiline in moderate Alzheimer’s disease: results of a randomized, double-blind, placebo-controlled phase II Trial (MAyflOwer RoAD). J Alzheimers Dis. 2017;58(4):1217–28.
pubmed: 28550255
pmcid: 5523913
Pollock BG, Mulsant BH, Rosen J, Sweet RA, Mazumdar S, Bharucha A, et al. Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. Am J Psychiatry. 2002;159(3):460–5.
pubmed: 11870012
De Deyn P, Jeste DV, Swanink R, Kostic D, Breder C, Carson WH, et al. Aripiprazole for the treatment of psychosis in patients with Alzheimer’s disease: a randomized, placebo-controlled study. J Clin Psychopharmacol. 2005;25(5):463–7.
pubmed: 16160622
De Deyn PP, Carrasco MM, Deberdt W, Jeandel C, Hay DP, Feldman PD, et al. Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer’s disease. Int J Geriatr Psychiatry. 2004;19(2):115–26.
pubmed: 14758577
Yanofski J. The dopamine dilemma: using stimulants and antipsychotics concurrently. Psychiatry (Edgmont). 2010;7(6):18–23.
Moreau C, Delval A, Defebvre L, Dujardin K, Duhamel A, Petyt G, et al. Methylphenidate for gait hypokinesia and freezing in patients with Parkinson’s disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trial. Lancet Neurol. 2012;11(7):589–96.
pubmed: 22658702
Hauser RA, Slawek J, Barone P, Dohin E, Surmann E, Asgharnejad M, et al. Evaluation of rotigotine transdermal patch for the treatment of apathy and motor symptoms in Parkinson’s disease. BMC Neurol. 2016;16:90.
pubmed: 27267880
pmcid: 4895976
Castrioto A, Thobois S, Anheim M, Quesada JL, Lhommée E, Klinger H, et al. A randomized controlled double-blind study of rotigotine on neuropsychiatric symptoms in de novo PD. NPJ Parkinsons Dis. 2020;6(1):41.
pubmed: 33319786
pmcid: 7738499
Barone P, Santangelo G, Morgante L, Onofrj M, Meco G, Abbruzzese G, et al. A randomized clinical trial to evaluate the effects of rasagiline on depressive symptoms in non-demented Parkinson’s disease patients. Eur J Neurol. 2015;22(8):1184–91.
pubmed: 25962410
pmcid: 4676931
Scherer RW, Drye L, Mintzer J, Lanctôt K, Rosenberg P, Herrmann N, et al. The Apathy in Dementia Methylphenidate Trial 2 (ADMET 2): study protocol for a randomized controlled trial. Trials. 2018;19(1):46.
pubmed: 29347996
pmcid: 5774109
Aripiprazole in the treatment of patients with psychosis associated with dementia of Alzheimer's type. https://ClinicalTrials.gov/show/NCT01438060 .
Devos D, Krystkowiak P, Clement F, Dujardin K, Cottencin O, Waucquier N, et al. Improvement of gait by chronic, high doses of methylphenidate in patients with advanced Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2007;78(5):470–5.
pubmed: 17098845
Ferreira-Vieira TH, Guimaraes IM, Silva FR, Ribeiro FM. Alzheimer’s disease: targeting the cholinergic system. Curr Neuropharmacol. 2016;14(1):101–15.
pubmed: 26813123
pmcid: 4787279
Mufson EJ, Counts SE, Perez SE, Ginsberg SD. Cholinergic system during the progression of Alzheimer’s disease: therapeutic implications. Expert Rev Neurother. 2008;8(11):1703–18.
pubmed: 18986241
pmcid: 2631573
Bohnen NI, Albin RL. The cholinergic system and Parkinson disease. Behav Brain Res. 2011;221(2):564–73.
pubmed: 20060022
Müller MLTM, Bohnen NI. Cholinergic dysfunction in Parkinson’s disease. Curr Neurol Neurosci Rep. 2013;13(9):377.
pubmed: 23943367
pmcid: 3991467
D’Souza GX, Waldvogel HJ. Targeting the cholinergic system to develop a novel therapy for Huntington’s disease. J Huntington’s Dis. 2016;5:333–42.
Perry EK, Irving D, Kerwin JM, McKeith IG, Thompson P, Collerton D, et al. Cholinergic transmitter and neurotrophic activities in Lewy body dementia: similarity to Parkinson’s and distinction from Alzheimer disease. Alzheimer Dis Assoc Disord. 1993;7(2):69–79.
pubmed: 8347330
Herrmann N, Rabheru K, Wang J, Binder C. Galantamine treatment of problematic behavior in Alzheimer disease: post-hoc analysis of pooled data from three large trials. Am J Geriatr Psychiatry. 2005;13(6):527–34.
pubmed: 15956273
Cummings JL, Schneider L, Tariot PN, Kershaw PR, Yuan W. Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer’s disease. Am J Psychiatry. 2004;161(3):532–8.
pubmed: 14992980
Kaufer D. Beyond the cholinergic hypothesis: the effect of metrifonate and other cholinesterase inhibitors on neuropsychiatric symptoms in Alzheimer’s disease. Dement Geriatr Cogn Disord. 1998;9(Suppl 2):8–14.
pubmed: 9718229
Morris JC, Cyrus PA, Orazem J, Mas J, Bieber F, Ruzicka BB, et al. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer’s disease. Neurology. 1998;50(5):1222–30.
pubmed: 9595967
Dubois B, McKeith I, Orgogozo JM, Collins O, Meulien D. A multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate Alzheimer’s disease: the MALT study. Int J Geriatr Psychiatry. 1999;14(11):973–82.
pubmed: 10556869
Raskind MA, Cyrus PA, Ruzicka BB, Gulanski BI. The effects of metrifonate on the cognitive, behavioral, and functional performance of Alzheimer’s disease patients. Metrifonate Study Group. J Clin Psychiatry. 1999;60(5):318–25.
pubmed: 10362441
Cummings JL, Nadel A, Masterman D, Cyrus PA. Efficacy of metrifonate in improving the psychiatric and behavioral disturbances of patients with Alzheimer’s disease. J Geriatr Psychiatry Neurol. 2001;14(2):101–8.
pubmed: 11419566
Tariot PN, Cummings JL, Katz IR, Mintzer J, Perdomo CA, Schwam EM, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer’s disease in the nursing home setting. J Am Geriatr Soc. 2001;49(12):1590–9.
pubmed: 11843990
Gauthier S, Feldman H, Hecker J, Vellas B, Ames D, Subbiah P, et al. Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer’s disease. Int Psychogeriatr. 2002;14(4):389–404.
pubmed: 12670060
Gauthier S, Feldman H, Hecker J, Vellas B, Emir B, Subbiah P. Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer’s disease. Curr Med Res Opin. 2002;18(6):347–54.
pubmed: 12442882
Holmes C, Wilkinson D, Dean C, Vethanayagam S, Olivieri S, Langley A, et al. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology. 2004;63(2):214–9.
pubmed: 15277611
Feldman H, Gauthier S, Hecker J, Vellas B, Xu Y, Ieni JR, et al. Efficacy and safety of donepezil in patients with more severe Alzheimer’s disease: a subgroup analysis from a randomized, placebo-controlled trial. Int J Geriatr Psychiatry. 2005;20(6):559–69.
pubmed: 15920715
Seltzer B, Zolnouni P, Nunez M, Goldman R, Kumar D, Ieni J, et al. Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial. Arch Neurol. 2004;61(12):1852–6.
pubmed: 15596605
Rea R, Carotenuto A, Traini E, Fasanaro AM, Manzo V, Amenta F. Apathy treatment in Alzheimer’s disease: interim results of the ASCOMALVA trial. J Alzheimers Dis. 2015;48(2):377–83.
pubmed: 26402001
Åhlin A, Nybäck H, Junthe T, Öhman G, Nordgren I. Tetrahydroaminoacridine in Alzheimer’s dementia: clinical and biochemical results of a double-blind crossover trial. Hum Psychopharmacol Clin Exp. 1991;6(2):109–18.
Devos D, Moreau C, Maltête D, Lefaucheur R, Kreisler A, Eusebio A, et al. Rivastigmine in apathetic but dementia and depression-free patients with Parkinson’s disease: a double-blind, placebo-controlled, randomised clinical trial. J Neurol Neurosurg Psychiatry. 2014;85(6):668–74.
pubmed: 24218528
McKeith I, Del Ser T, Spano P, Emre M, Wesnes K, Anand R, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet. 2000;356(9247):2031–6.
pubmed: 11145488
Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV. Efficacy of galantamine in probable vascular dementia and Alzheimer’s disease combined with cerebrovascular disease: a randomised trial. Lancet. 2002;359(9314):1283–90.
pubmed: 11965273
Carotenuto A, Rea R, Traini E, Fasanaro AM, Ricci G, Manzo V, et al. The effect of the association between donepezil and choline alphoscerate on behavioral disturbances in Alzheimer’s disease: interim results of the ASCOMALVA trial. J Alzheimers Dis. 2017;56(2):805–15.
pubmed: 28035924
Švob Štrac D, Pivac N, Mück-Šeler D. The serotonergic system and cognitive function. Transl Neurosci. 2016;7(1):35–49.
pubmed: 28123820
pmcid: 5017596
Šimić G, Babić Leko M, Wray S, Harrington CR, Delalle I, Jovanov-Milošević N, et al. Monoaminergic neuropathology in Alzheimer’s disease. Prog Neurobiol. 2017;151:101–38.
pubmed: 27084356
Huot P, Fox SH, Brotchie JM. The serotonergic system in Parkinson’s disease. Prog Neurobiol. 2011;95(2):163–212.
pubmed: 21878363
Pla P, Orvoen S, Saudou F, David DJ, Humbert S. Mood disorders in Huntington’s disease: from behavior to cellular and molecular mechanisms. Front Behav Neurosci. 2014;8:135.
pubmed: 24795586
pmcid: 4005937
van der Zande JJ, Joling M, Happach IG, Vriend C, Scheltens P, Booij J, et al. Serotonergic deficits in dementia with Lewy bodies with concomitant Alzheimer’s disease pathology: an (123)I-FP-CIT SPECT study. Neuroimage Clin. 2020;25:102062.
pubmed: 31790878
Lawlor BA, Sunderland T, Mellow AM, Hill JL, Molchan SE, Murphy DL. Hyperresponsivity to the serotonin agonist m-chlorophenylpiperazine in Alzheimer’s disease. A controlled study. Arch Gen Psychiatry. 1989;46(6):542–9.
pubmed: 2730278
Lanctôt KL, Herrmann N, van Reekum R, Eryavec G, Naranjo CA. Gender, aggression and serotonergic function are associated with response to sertraline for behavioral disturbances in Alzheimer’s disease. Int J Geriatr Psychiatry. 2002;17(6):531–41.
pubmed: 12112177
Zhou T, Wang J, Xin C, Kong L, Wang C. Effect of memantine combined with citalopram on cognition of BPSD and moderate Alzheimer’s disease: a clinical trial. Exp Ther Med. 2019;17(3):1625–30.
pubmed: 30783429
Leonpacher AK, Peters ME, Drye LT, Makino KM, Newell JA, Devanand DP, et al. Effects of citalopram on neuropsychiatric symptoms in Alzheimer’s dementia: evidence from the CitAD study. Am J Psychiatry. 2016;173(5):473–80.
pubmed: 27032628
Nyth AL, Gottfries CG. The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. A Nordic multicentre study. Br J Psychiatry. 1990;157:894–901.
pubmed: 1705151
Lebert F, Stekke W, Hasenbroekx C, Pasquier F. Frontotemporal dementia: a randomised, controlled trial with trazodone. Dement Geriatr Cogn Disord. 2004;17(4):355–9.
pubmed: 15178953
Ranjbar-Slamloo Y, Fazlali Z. Dopamine and noradrenaline in the brain; overlapping or dissociate functions? Front Mol Neurosci. 2020;12:334.
pubmed: 32038164
pmcid: 6986277
Gannon M, Wang Q. Complex noradrenergic dysfunction in Alzheimer’s disease: low norepinephrine input is not always to blame. Brain Res. 2019;1702:12–6.
pubmed: 29307592
Paredes-Rodriguez E, Vegas-Suarez S, Morera-Herreras T, De Deurwaerdere P, Miguelez C. The noradrenergic system in Parkinson’s disease. Front Pharmacol. 2020;11:435.
pubmed: 32322208
pmcid: 7157437
Spokes EGS. Neurochemical alterations in Huntington’s chorea: a study of post-mortem brain tissue. Brain. 1980;103(1):179–210.
pubmed: 6102490
Szot P, White SS, Greenup JL, Leverenz JB, Peskind ER, Raskind MA. Compensatory changes in the noradrenergic nervous system in the locus ceruleus and hippocampus of postmortem subjects with Alzheimer’s disease and dementia with Lewy bodies. J Neurosci. 2006;26(2):467–78.
pubmed: 16407544
pmcid: 6674412
van Dyck CH, Arnsten AFT, Padala PR, Brawman-Mintzer O, Lerner AJ, Porsteinsson AP, et al. Neurobiologic rationale for treatment of apathy in alzheimer’s disease with methylphenidate. Am J Geriatr Psychiatry. 2021;29(1):51–62.
pubmed: 32461027
Maier F, Spottke A, Bach JP, Bartels C, Buerger K, Dodel R, et al. Bupropion for the treatment of apathy in Alzheimer disease: a randomized clinical trial. JAMA Netw Open. 2020;3(5):e206027.
pubmed: 32463470
pmcid: 7256670
Gelderblom H, Wüstenberg T, McLean T, Mütze L, Fischer W, Saft C, et al. Bupropion for the treatment of apathy in Huntington’s disease: a multicenter, randomised, double-blind, placebo-controlled, prospective crossover trial. PLoS ONE. 2017;12(3):e0173872.
pubmed: 28323838
pmcid: 5360242
Wu C, Sun D. GABA receptors in brain development, function, and injury. Metab Brain Dis. 2015;30(2):367–79.
pubmed: 24820774
Li Y, Sun H, Chen Z, Xu H, Bu G, Zheng H. Implications of GABAergic neurotransmission in Alzheimer’s disease. Front Aging Neurosci. 2016;8:31.
pubmed: 26941642
pmcid: 4763334
de Jong PJ, Lakke JP, Teelken AW. CSF GABA levels in Parkinson’s disease. Adv Neurol. 1984;40:427–30.
pubmed: 6695622
Tosca P, Canevari L, Di Paolo E, Ferrari R, Verzé S, Zerbi F, et al. Glutamate and GABA levels in CSF from patients affected by dementia and olivo-ponto-cerebellar atrophy. Acta Neurol Scand. 1992;85(6):430–5.
pubmed: 1353649
Reynolds GP, Pearson SJ, Heathfield KWG. Dementia in Huntington’s disease is associated with neurochemical deficits in the caudate nucleus, not the cerebral cortex. Neurosci Lett. 1990;113(1):95–100.
pubmed: 1973277
Huey ED, Putnam KT, Grafman J. A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia. Neurology. 2006;66(1):17–22.
pubmed: 16401839
Lanctôt KL, Herrmann N, Rothenburg L, Eryavec G. Behavioral correlates of GABAergic disruption in Alzheimer’s disease. Int Psychogeriatr. 2007;19(1):151–8.
pubmed: 16870038
Sival RC, Haffmans PM, Jansen PA, Duursma SA, Eikelenboom P. Sodium valproate in the treatment of aggressive behavior in patients with dementia—a randomized placebo controlled clinical trial. Int J Geriatr Psychiatry. 2002;17(6):579–85.
pubmed: 12112183
Zhou Y, Danbolt NC. Glutamate as a neurotransmitter in the healthy brain. J Neural Transm (Vienna). 2014;121(8):799–817.
Wang R, Reddy PH. Role of glutamate and NMDA receptors in Alzheimer’s disease. J Alzheimers Dis. 2017;57:1041–8.
pubmed: 27662322
pmcid: 5791143
Madeira C, Vargas-Lopes C, Brandão CO, Reis T, Laks J, Panizzutti R, et al. Elevated glutamate and glutamine levels in the cerebrospinal fluid of patients with probable Alzheimer’s disease and depression. Front Psychiatry. 2018;9:561.
pubmed: 30459657
pmcid: 6232456
Iovino L, Tremblay ME, Civiero L. Glutamate-induced excitotoxicity in Parkinson’s disease: the role of glial cells. J Pharmacol Sci. 2020;144(3):151–64.
pubmed: 32807662
Albasanz JL, Dalfó E, Ferrer I, Martín M. Impaired metabotropic glutamate receptor/phospholipase C signaling pathway in the cerebral cortex in Alzheimer’s disease and dementia with Lewy bodies correlates with stage of Alzheimer’s-disease-related changes. Neurobiol Dis. 2005;20(3):685–93.
pubmed: 15949941
Araki T, Wake R, Miyaoka T, Kawakami K, Nagahama M, Furuya M, et al. The effects of combine treatment of memantine and donepezil on Alzheimer’s disease patients and its relationship with cerebral blood flow in the prefrontal area. Int J Geriatr Psychiatry. 2014;29(9):881–9.
pubmed: 24436135
Gauthier S, Wirth Y, Möbius HJ. Effects of memantine on behavioural symptoms in Alzheimer’s disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies. Int J Geriatr Psychiatry. 2005;20(5):459–64.
pubmed: 15852444
Reisberg B, Doody R, Stöffler A, Schmitt F, Ferris S, Möbius HJ. Memantine in moderate-to-severe Alzheimer’s disease. N Engl J Med. 2003;348(14):1333–41.
pubmed: 12672860
Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004;291(3):317–24.
pubmed: 14734594
Winblad B, Poritis N. Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry. 1999;14(2):135–46.
pubmed: 10885864
Haas HL, Sergeeva OA, Selbach O. Histamine in the nervous system. Physiol Rev. 2008;88(3):1183–241.
pubmed: 18626069
Thakkar MM. Histamine in the regulation of wakefulness. Sleep Med Rev. 2011;15(1):65–74.
pubmed: 20851648
Sedeyn JC, Wu H, Hobbs RD, Levin EC, Nagele RG, Venkataraman V. Histamine induces Alzheimer’s disease-like blood brain barrier breach and local cellular responses in mouse brain organotypic cultures. BioMed Res Int. 2015;2015:937148.
pubmed: 26697497
pmcid: 4677161
Zlomuzica A, Dere D, Binder S, De Souza Silva MA, Huston JP, Dere E. Neuronal histamine and cognitive symptoms in Alzheimer’s disease. Neuropharmacology. 2016;106:135–45.
pubmed: 26025658
Rinne JO, Anichtchik OV, Eriksson KS, Kaslin J, Tuomisto L, Kalimo H, et al. Increased brain histamine levels in Parkinson’s disease but not in multiple system atrophy. J Neurochem. 2002;81(5):954–60.
pubmed: 12065607
van Wamelen DJ, Shan L, Aziz NA, Anink JJ, Bao AM, Roos RA, et al. Functional increase of brain histaminergic signaling in Huntington’s disease. Brain Pathol. 2011;21(4):419–27.
pubmed: 21106039
Naddafi F, Mirshafiey A. The neglected role of histamine in Alzheimer’s disease. Am J Alzheimer’s Dis Other Dement. 2013;28(4):327–36.
Benarroch EE, Schmeichel AM, Parisi JE, Low PA. Histaminergic tuberomammillary neuron loss in multiple system atrophy and dementia with Lewy bodies. Mov Disord. 2015;30(8):1133–9.
pubmed: 26095065
Stasiak A, Mussur M, Unzeta M, Łażewska D, Kiec-Kononowicz K, Fogel WA. The central histamine level in rat model of vascular dementia. J Physiol Pharmacol. 2011;62:549–58.
pubmed: 22204803
Verdejo-García A, Rivas-Pérez C, López-Torrecillas F, Pérez-García M. Differential impact of severity of drug use on frontal behavioral symptoms. Addict Behav. 2006;31(8):1373–82.
pubmed: 16326022
Yoshizawa M, Tashiro M, Fukudo S, Yanai K, Utsumi A, Kano M, et al. Increased brain histamine H1 receptor binding in patients with anorexia nervosa. Biol Psychiatry (1969). 2009;65(4):329–35.
Horner WE, Johnson DE, Schmidt AW, Rollema H. Methylphenidate and atomoxetine increase histamine release in rat prefrontal cortex. Eur J Pharmacol. 2007;558(1):96–7.
pubmed: 17198700
Ebrahim IO, Howard RS, Kopelman MD, Sharief MK, Williams AJ. The hypocretin/orexin system. J R Soc Med. 2002;95(5):227–30.
pubmed: 11983761
pmcid: 1279673
Um YH, Lim HK. Orexin and Alzheimer’s disease: a new perspective. Psychiatry Investig. 2020;17(7):621–6.
pubmed: 32517419
Liu C, Xue Y, Liu M-F, Wang Y, Chen L. Orexin and Parkinson’s disease: a protective neuropeptide with therapeutic potential. Neurochem Int. 2020;138:104754.
pubmed: 32422324
Petersén Å, Gil J, Maat-Schieman MLC, Björkqvist M, Tanila H, Araújo IM, et al. Orexin loss in Huntington’s disease. Hum Mol Genet. 2005;14(1):39–47.
pubmed: 15525658
Çoban A, Bilgiç B, Lohmann E, Küçükali Cİ, Benbir G, Karadeniz D, et al. Reduced orexin—a levels in frontotemporal dementia: possible association with sleep disturbance. Am J Alzheimer’s Dis Other Dement. 2013;28(6):606–11.
Song J, Kim E, Kim C-H, Song H-T, Lee JE. The role of orexin in post-stroke inflammation, cognitive decline, and depression. Mol Brain. 2015;8:16.
pubmed: 25884812
pmcid: 4357085
Lessig S, Ubhi K, Galasko D, Adame A, Pham E, Remidios K, et al. Reduced hypocretin (orexin) levels in dementia with Lewy bodies. NeuroReport. 2010;21(11):756–60.
pubmed: 20531237
pmcid: 2908368
Nocjar C, Zhang J, Feng P, Panksepp J. The social defeat animal model of depression shows diminished levels of orexin in mesocortical regions of the dopamine system, and of dynorphin and orexin in the hypothalamus. Neuroscience. 2012;218:138–53.
pubmed: 22626650
Holzer P, Reichmann F, Farzi A, Neuropeptide Y. peptide YY and pancreatic polypeptide in the gut-brain axis. Neuropeptides. 2012;46(6):261–74.
pubmed: 22979996
pmcid: 3516703
Ferrini F, Salio C, Lossi L, Merighi A. Ghrelin in central neurons. Curr Neuropharmacol. 2009;7(1):37–49.
pubmed: 19721816
pmcid: 2724662
Serrenho D, Santos SD, Carvalho AL. The role of ghrelin in regulating synaptic function and plasticity of feeding-associated circuits. Front Cell Neurosci. 2019;13:205.
pubmed: 31191250
pmcid: 6546032
Pedrini S, Gupta VB, Hone E, Doecke J, O’Bryant S, James I, et al. A blood-based biomarker panel indicates IL-10 and IL-12/23p40 are jointly associated as predictors of β-amyloid load in an AD cohort. Sci Rep. 2017;7(1):14057.
pubmed: 29070909
pmcid: 5656630
Shi L, Du X, Jiang H, Xie J. Ghrelin and neurodegenerative disorders—a review. Mol Neurobiol. 2017;54(2):1144–55.
pubmed: 26809582
Yang D, Zhao D, Ali Shah SZ, Wu W, Lai M, Zhang X, et al. The role of the gut microbiota in the pathogenesis of Parkinson’s disease. Front Neurol. 2019;10:1155.
pubmed: 31781020
pmcid: 6851172
Hornsby AKE, Buntwal L, Carisi MC, Santos VV, Johnston F, Roberts LD, et al. Unacylated-ghrelin impairs hippocampal neurogenesis and memory in mice and is altered in parkinson’s dementia in humans. Cell Rep Med. 2020;1(7):100120.
pubmed: 33103129
pmcid: 7575905
Cong W, Cai H, Wang R, Daimon CM, Maudsley S, Raber K, et al. Altered hypothalamic protein expression in a rat model of Huntington’s disease. PLoS ONE. 2012;7(10):e47240.
pubmed: 23094041
pmcid: 3475691
Stoyanova II. Ghrelin: a link between ageing, metabolism and neurodegenerative disorders. Neurobiol Dis. 2014;72:72–83.
pubmed: 25173805
Yamada C, Mogami S, Kanno H, Hattori T. Peptide YY causes apathy-like behavior via the dopamine D2 receptor in repeated water-immersed mice. Mol Neurobiol. 2018;55(9):7555–66.
pubmed: 29429048
pmcid: 6096978
Bjorness TE, Greene RW. Adenosine and sleep. Curr Neuropharmacol. 2009;7(3):238–45.
pubmed: 20190965
pmcid: 2769007
Chen JF. Adenosine receptor control of cognition in normal and disease. Int Rev Neurobiol. 2014;119:257–307.
pubmed: 25175970
Anisur R. The role of adenosine in Alzheimers disease. Curr Neuropharmacol. 2009;7(3):207–16.
Nazario LR, da Silva RS, Bonan CD. Targeting adenosine signaling in Parkinson’s disease: from pharmacological to non-pharmacological approaches. Front Neurosci. 2017;11:658.
pubmed: 29217998
pmcid: 5703841
Uchida S, Kadowaki-Horita T, Kanda T. Effects of the adenosine A2A receptor antagonist on cognitive dysfunction in Parkinson’s disease. Int Rev Neurobiol. 2014;119:169–89.
pubmed: 25175966
Varani K, Rigamonti D, Sipione S, Camurri A, Borea PA, Cattabeni F, et al. Aberrant amplification of A(2A) receptor signaling in striatal cells expressing mutant huntingtin. Faseb j. 2001;15(7):1245–7.
pubmed: 11344102
Tarditi A, Camurri A, Varani K, Borea PA, Woodman B, Bates G, et al. Early and transient alteration of adenosine A2A receptor signaling in a mouse model of Huntington disease. Neurobiol Dis. 2006;23(1):44–53.
pubmed: 16651003
Gomes CV, Kaster MP, Tomé AR, Agostinho PM, Cunha RA. Adenosine receptors and brain diseases: neuroprotection and neurodegeneration. Biochim Biophys Acta. 2011;1808(5):1380–99.
pubmed: 21145878
Martire A, Pepponi R, Domenici MR, Ferrante A, Chiodi V, Popoli P. BDNF prevents NMDA-induced toxicity in models of Huntington’s disease: the effects are genotype specific and adenosine A2A receptor is involved. J Neurochem. 2013;125(2):225–35.
pubmed: 23363456
Tyebji S, Saavedra A, Canas PM, Pliassova A, Delgado-García JM, Alberch J, et al. Hyperactivation of D1 and A2A receptors contributes to cognitive dysfunction in Huntington’s disease. Neurobiol Dis. 2015;74:41–57.
pubmed: 25449908
Carvalho K, Faivre E, Pietrowski MJ, Marques X, Gomez-Murcia V, Deleau A, et al. Exacerbation of C1q dysregulation, synaptic loss and memory deficits in tau pathology linked to neuronal adenosine A2A receptor. Brain. 2019;142(11):3636–54.
pubmed: 31599329
pmcid: 6821333
Gussago C, Arosio B, Casati M, Ferri E, Gualandris F, Tedone E, et al. Different adenosine A 2A receptor expression in peripheral cells from elderly patients with vascular dementia and Alzheimer’s disease. J Alzheimers Dis. 2014;40:45–9.
pubmed: 24321892
Garcia-Esparcia P, López-González I, Grau-Rivera O, García-Garrido MF, Konetti A, Llorens F, et al. Dementia with lewy bodies: molecular pathology in the frontal cortex in typical and rapidly progressive forms. Front Neurol. 2017;8:89.
pubmed: 28348546
pmcid: 5346561
Nagayama H, Kano O, Murakami H, Ono K, Hamada M, Toda T, et al. Effect of istradefylline on mood disorders in Parkinson’s disease. J Neurol Sci. 2019;396:78–83.
pubmed: 30423541
Orr AG, Lo I, Schumacher H, Ho K, Gill M, Guo W, et al. Istradefylline reduces memory deficits in aging mice with amyloid pathology. Neurobiol Dis. 2018;110:29–36.
pubmed: 29100987
Li W, Silva HB, Real J, Wang Y-M, Rial D, Li P, et al. Inactivation of adenosine A2A receptors reverses working memory deficits at early stages of Huntington’s disease models. Neurobiol Dis. 2015;79:70–80.
pubmed: 25892655
Rosenberg PB, Lanctôt KL, Herrmann N, Mintzer JE, Porsteinsson AP, Sun X, et al. Changes in neuropsychiatric inventory associated with semagacestat treatment of Alzheimer’s disease. J Alzheimers Dis. 2016;54(1):373–81.
pubmed: 27567808
Trzepacz PT, Cummings J, Konechnik T, Forrester TD, Chang C, Dennehy EB, et al. Mibampator (LY451395) randomized clinical trial for agitation/aggression in Alzheimer’s disease. Int Psychogeriatr. 2013;25(5):707–19.
pubmed: 23257314
Kim SY, Choi SH, Rollema H, Schwam EM, McRae T, Dubrava S, et al. Phase II crossover trial of varenicline in mild-to-moderate Alzheimer’s disease. Dement Geriatr Cogn Disord. 2014;37(3–4):232–45.
pubmed: 24247022
Ban TA, Morey L, Aguglia E, Azzarelli O, Balsano F, Marigliano V, et al. Nimodipine in the treatment of old age dementias. Prog Neuropsychopharmacol Biol Psychiatry. 1990;14(4):525–51.
pubmed: 2236581
Scripnikov A, Khomenko A, Napryeyenko O. Effects of Ginkgo biloba extract EGb 761 on neuropsychiatric symptoms of dementia: findings from a randomised controlled trial. Wien Med Wochenschr. 2007;157(13–14):295–300.
pubmed: 17704975
Bachinskaya N, Hoerr R, Ihl R. Alleviating neuropsychiatric symptoms in dementia: the effects of Ginkgo biloba extract EGb 761. Findings from a randomized controlled trial. Neuropsychiatr Dis Treat. 2011;7:209–15.
pubmed: 21573082
pmcid: 3090284
Bayer A, Bokonjic R, Booya N. European pentoxifylline multi-infarct dementia study. Eur Neurol. 1996;36(5):315–21.
Finger EC, MacKinley J, Blair M, Oliver LD, Jesso S, Tartaglia MC, et al. Oxytocin for frontotemporal dementia: a randomized dose-finding study of safety and tolerability. Neurology. 2015;84(2):174–81.
pubmed: 25503617
pmcid: 4336088
Callegari I, Mattei C, Benassi F, Krueger F, Grafman J, Yaldizli Ö, et al. Agomelatine Improves Apathy in Frontotemporal Dementia. Neurodegener Dis. 2016;16(5–6):352–6.
pubmed: 27229348
Ruthirakuhan MT, Herrmann N, Abraham EH, Chan S, Lanctôt KL. Pharmacological interventions for apathy in Alzheimer's disease. Cochrane Database Syst Rev. 2018;5(5):CD012197.
Charach G, Karniel E, Grosskopf I, Rabinovich A, Charach L. Methylphenidate has mild hyperglycemic and hypokalemia effects and increases leukocyte and neutrophil counts. Medicine (Baltimore). 2020;99(27):e20931-e.
Shin J-Y, Roughead EE, Park B-J, Pratt NL. Cardiovascular safety of methylphenidate among children and young people with attention-deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study. BMJ. 2016;353:i2550.
pubmed: 27245699
pmcid: 4887614
Gauthier S, Loft H, Cummings J. Improvement in behavioural symptoms in patients with moderate to severe Alzheimer’s disease by memantine: a pooled data analysis. Int J Geriatr Psychiatry. 2008;23(5):537–45.
pubmed: 18058838
Ohbe H, Jo T, Matsui H, Fushimi K, Yasunaga H. Cholinergic crisis caused by cholinesterase inhibitors: a retrospective nationwide database study. J Med Toxicol. 2018;14(3):237–41.
pubmed: 29907949
pmcid: 6097965
Barthold D, Joyce G, Ferido P, Drabo EF, Marcum ZA, Gray SL, et al. Pharmaceutical treatment for Alzheimer’s disease and related dementias: utilization and disparities. J Alzheimer’s Dis JAD. 2020;76(2):579–89.
Tampi RR, Tampi DJ, Balachandran S, Srinivasan S. Antipsychotic use in dementia: a systematic review of benefits and risks from meta-analyses. Ther Adv Chronic Dis. 2016;7(5):229–45.
pubmed: 27583123
pmcid: 4994396
Porsteinsson AP, Drye LT, Pollock BG, Devanand DP, Frangakis C, Ismail Z, et al. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA. 2014;311(7):682–91.
pubmed: 24549548
pmcid: 4086818
Qirjazi E, McArthur E, Nash DM, Dixon SN, Weir MA, Vasudev A, et al. Risk of ventricular arrhythmia with citalopram and escitalopram: a population-based study. PLoS ONE. 2016;11(8):e0160768-e.
Chen F, Jin L, Nie Z. Safety and efficacy of rotigotine for treating Parkinson’s disease: a meta-analysis of randomised controlled trials. J Pharm Pharm Sci. 2017;20:285–94.
pubmed: 28810946
Carbone F, Djamshidian A, Seppi K, Poewe W. Apomorphine for parkinson’s disease: efficacy and safety of current and new formulations. CNS Drugs. 2019;33(9):905–18.
pubmed: 31473980
pmcid: 6776563
Ohsawa M, Tanaka Y, Ehara Y, Makita S, Onaka K. A possibility of simultaneous treatment with the multicomponent drug, Ninjin’yoeito, for anorexia, apathy, and cognitive dysfunction in frail Alzheimer’s disease patients: an open-label pilot study. J Alzheimers Dis Rep. 2017;1(1):229–35.
pubmed: 30480240
pmcid: 6159634
Van Reekum R, Bayley M, Garner S, Burke IM, Fawcett S, Hart A, et al. N of 1 study: amantadine for the amotivational syndrome in a patient with traumatic brain injury. Brain Inj. 1995;9(1):49–53.
pubmed: 7874096
Postma JU, Van Tilburg W. Visual hallucinations and delirium during treatment with amantadine (Symmetrel). J Am Geriatr Soc. 1975;23(5):212–5.
pubmed: 123540
Theleritis CG, Siarkos KT, Politis AM. Unmet needs in pharmacological treatment of apathy in Alzheimer’s disease: a systematic review. Front Pharmacol. 2019;10:1108.
pubmed: 31680942
pmcid: 6797825
Matsuzono K, Hishikawa N, Ohta Y, Yamashita T, Deguchi K, Nakano Y, et al. Combination therapy of cholinesterase inhibitor (donepezil or galantamine) plus memantine in the okayama memantine study. J Alzheimers Dis. 2015;45(3):771–80.
pubmed: 25624417
Lanctôt KL, Agüera-Ortiz L, Brodaty H, Francis PT, Geda YE, Ismail Z, et al. Apathy associated with neurocognitive disorders: recent progress and future directions. Alzheimers Dement. 2017;13(1):84–100.
pubmed: 27362291
Mohammad D, Ellis C, Rau A, Rosenberg PB, Mintzer J, Ruthirakuhan M, et al. Psychometric properties of apathy scales in dementia: a systematic review. J Alzheimers Dis. 2018;66(3):1065–82.
pubmed: 30400094
Cummings J, Friedman JH, Garibaldi G, Jones M, Macfadden W, Marsh L, et al. Apathy in neurodegenerative diseases: recommendations on the design of clinical trials. J Geriatr Psychiatry Neurol. 2015;28(3):159–73.
pubmed: 25809634
Glenn M. The Apathy Evaluation Scale. The center for outcome measurement in brain injury. 2005. http://www.tbims.org/combi/aes .
Cummings JL. The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology. 1997;48(5 Suppl 6):S10–6.
pubmed: 9153155
Cai Y, Li L, Xu C, Wang Z. The effectiveness of non-pharmacological interventions on apathy in patients with dementia: a systematic review of systematic reviews. Worldviews Evid Based Nurs. 2020;17(4):311–8.
pubmed: 32767834